Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multiple-dose randomized study of recifercept in children with achondroplasia
jRCT2061220040Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial of recifercept in achondroplasia (ACH) (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with treatment-emergent treatment-related adverse events, Change in height from baseline and 1 more. Started Sep 2022; status: completed.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2061220040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220040.